These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 8504432

  • 1. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.
    Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF.
    Cancer Res; 1993 Jun 15; 53(12):2912-8. PubMed ID: 8504432
    [Abstract] [Full Text] [Related]

  • 2. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.
    Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM, Dvorak HF.
    Cancer Res; 1995 Jan 15; 55(2):360-8. PubMed ID: 7812969
    [Abstract] [Full Text] [Related]

  • 3. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G.
    Cancer; 1999 Jan 01; 85(1):178-87. PubMed ID: 9921991
    [Abstract] [Full Text] [Related]

  • 4. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
    Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, Brown LF.
    Lab Invest; 1996 Jun 01; 74(6):1105-15. PubMed ID: 8667614
    [Abstract] [Full Text] [Related]

  • 5. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
    Luo JC, Toyoda M, Shibuya M.
    Cancer Res; 1998 Jun 15; 58(12):2594-600. PubMed ID: 9635584
    [Abstract] [Full Text] [Related]

  • 6. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.
    Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF.
    Cancer Res; 1993 Oct 01; 53(19):4727-35. PubMed ID: 8402650
    [Abstract] [Full Text] [Related]

  • 7. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors.
    Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M.
    Cancer Res; 1998 Jun 15; 58(12):2652-60. PubMed ID: 9635593
    [Abstract] [Full Text] [Related]

  • 8. Vascular permeability factor gene expression in normal and neoplastic human ovaries.
    Olson TA, Mohanraj D, Carson LF, Ramakrishnan S.
    Cancer Res; 1994 Jan 01; 54(1):276-80. PubMed ID: 8261452
    [Abstract] [Full Text] [Related]

  • 9. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ.
    Clin Cancer Res; 2000 Mar 01; 6(3):957-65. PubMed ID: 10741721
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
    Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB, Ellis LM.
    Clin Cancer Res; 1999 Nov 01; 5(11):3364-8. PubMed ID: 10589746
    [Abstract] [Full Text] [Related]

  • 11. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
    van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM, Hoekman K.
    Clin Cancer Res; 2002 Dec 01; 8(12):3747-54. PubMed ID: 12473585
    [Abstract] [Full Text] [Related]

  • 12. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M.
    Oncol Rep; 2003 Dec 01; 10(1):89-95. PubMed ID: 12469150
    [Abstract] [Full Text] [Related]

  • 13. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer.
    Liu CD, Tilch L, Kwan D, McFadden DW.
    J Surg Res; 2002 Jan 01; 102(1):31-4. PubMed ID: 11792148
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies.
    Sioussat TM, Dvorak HF, Brock TA, Senger DR.
    Arch Biochem Biophys; 1993 Feb 15; 301(1):15-20. PubMed ID: 8442657
    [Abstract] [Full Text] [Related]

  • 15. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
    Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H.
    Anticancer Res; 2000 Feb 15; 20(1A):155-60. PubMed ID: 10769648
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma.
    Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, Brown LF.
    Cancer; 1996 Aug 01; 78(3):454-60. PubMed ID: 8697391
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.